Arovella Therapeutics Ltd has released a press release.
Appendix 4E and Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- S&P DJI Announces March 2025 Quarterly Rebalance
- Research Agreement with University of North Carolina
- Reinstatement to Official Quotation
- Prospectus
- Arovella $15m Placement to fund Phase 1
Later from Arovella Therapeutics
- S&P DJI Announces September 2025 Quarterly Rebalance
- Arovella receives R&D tax rebate of $3.21 million
- CLDN18.2 CAR-T cells eliminate pancreatic cancer cells
- Positive FDA Type D Meeting Outcome
- Arovella Therapeutics appoints former CSL CSO Dr Andrew Nash as Non-executive Director
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics